Peptide Therapy in BC: BPC-157, Sermorelin, and Growth Hormone Peptides — What's Legal, What Works, and Where to Get Physician-Prescribed Peptides in British Columbia (2026)

Last Updated: April 2026

Reviewed by Sarah K., MSc Health Sciences | BCMedicalAccess.ca Editorial Team

---

⚠️ Important Notice

This article is for informational purposes only and does not constitute medical advice. Peptide therapies may not be approved by Health Canada for all indications. Consult a licensed physician before pursuing any treatment. BCMedicalAccess.ca is a healthcare navigation resource, not a medical provider.

---

If you've spent time on health-optimization Reddit, listened to a longevity podcast, or scrolled through a particularly aggressive Instagram feed, you've encountered peptides — usually with claims that range from "speeds tendon healing" to "reverses aging." The substance behind those claims is mixed. Some peptides have decades of clinical data. Others have a few rodent studies and a robust online marketplace. And in Canada, most of them sit in a regulatory grey zone that's actively shifting.

This guide is for BC residents who've already read the basics and want a sober answer to four questions: which peptides are these conversations actually about, what does the human evidence say, what's legal in Canada, and what does a legitimate prescribing pathway in BC actually look like.

What Are Peptides and Why Are They Getting Attention?

A peptide is a short chain of amino acids — anywhere from two to roughly fifty — that acts as a signalling molecule in the body. Insulin is a peptide. So is oxytocin. So is semaglutide (the active ingredient in Ozempic and Wegovy), which has fundamentally changed obesity medicine over the past three years. Peptides aren't fringe — they're a major drug class with extensive pharmaceutical history [1].

The "peptide therapy" the biohacking community is talking about is a narrower subset: synthetic peptides marketed for tissue repair, growth hormone stimulation, sexual function, anti-aging, and recovery. The interest is driven by a real biological premise (peptides are precise signalling tools that activate specific receptors) and by a narrative that's outpaced the evidence in most cases.

The single most important distinction for any BC resident considering peptide therapy is this: "research-grade" peptides ordered from online suppliers are not the same as physician-prescribed peptides dispensed by a licensed Canadian compounding pharmacy. The compounds may share a chemical name, but the supply chain, purity verification, sterility, dosing accuracy, and medical oversight are not comparable. One is regulated medicine. The other is, in regulatory terms, an unauthorized drug — and Health Canada has been enforcing against it [2].

The Peptides BC Patients Are Actually Asking About

BPC-157 (Body Protection Compound)

BPC-157 is a 15-amino-acid peptide derived from a fragment of a protein found in human gastric juice. The animal data is genuinely impressive — over 100 preclinical studies across three decades suggest accelerated healing of tendons, ligaments, gut lining, and even nerve tissue [3]. The catch is the human data. A 2025 systematic review in the American Journal of Sports Medicine screened 544 articles on BPC-157 for orthopaedic applications and found only one clinical study that met inclusion criteria [4].

BPC-157 is not approved by any regulatory agency in the world — not Health Canada, not the FDA, not the EMA. In late 2023, the FDA placed it in Category 2 of substances "presenting significant safety risks," citing concerns about immune reactions, peptide impurities, and the lack of human safety data — effectively blocking US compounding pharmacies from preparing it [5]. The World Anti-Doping Agency banned it under S0 (Unapproved Substances) in 2022. In April 2025, Health Canada issued a public advisory after seizing unauthorized injectable peptide drugs — including BPC-157 — sold by a Quebec-based supplier [2]. This is the most-asked-about peptide and arguably the one with the widest gap between online enthusiasm and clinical validation.

Sermorelin

Sermorelin is a 29-amino-acid peptide that mimics growth hormone-releasing hormone (GHRH). It binds the same pituitary receptor your own GHRH targets, prompting your pituitary to release growth hormone in pulses similar to natural patterns. Of the peptides on this list, sermorelin has the longest regulatory history — it was sold under the brand name Geref, FDA-approved in the 1990s for paediatric growth hormone deficiency, before the manufacturer voluntarily discontinued the branded product in 2008 for commercial reasons [6].

Sermorelin is no longer available as a finished pharmaceutical product in Canada, but the molecule itself remains accessible through compounding pharmacies on a physician's prescription. The clinical evidence in healthy adults using sermorelin for "anti-aging" or body composition is limited — most published data is from the original paediatric GHD studies and small adult GHD trials. Patient-reported effects (improved sleep, better recovery, modest body composition change) appear within 1–2 weeks anecdotally, though randomized data in healthy adults is sparse. Side effects are generally mild: injection site reactions, occasional flushing, vivid dreams.

Ipamorelin / CJC-1295

These two peptides are almost always prescribed together as a "stack." Ipamorelin is a selective growth hormone secretagogue — it activates the ghrelin receptor on the pituitary to trigger GH release, but unlike older peptides in this class, it doesn't significantly raise cortisol or prolactin. CJC-1295 is a long-acting GHRH analog (the "DAC" version binds to albumin, extending its half-life to days). Together, they activate two different pituitary pathways, producing a larger and longer GH pulse than either alone.

Neither is approved by Health Canada or the FDA for any indication [7]. The 2024 FDA Pharmacy Compounding Advisory Committee briefing concluded that no growth hormone secretagogues — including ipamorelin — have been approved for adult GH deficiency [7]. Both are accessed off-label in BC through compounding pharmacies, and the regulatory status is in flux: the FDA briefly placed CJC-1295 and ipamorelin in Category 2 in 2023, though legal challenges have complicated enforcement. Human safety data is limited to small studies; no large randomized controlled trials in healthy adults exist. They remain among the most commonly prescribed peptides in private optimization clinics — a popularity that exceeds the published evidence base.

TB-500 (Thymosin Beta-4)

TB-500 is technically a 17-amino-acid synthetic fragment of thymosin beta-4, a naturally occurring protein involved in actin regulation, tissue repair, and inflammation modulation. It's the cousin compound to BPC-157 in the recovery-peptide conversation, marketed for soft tissue and tendon healing.

The human evidence is more developed than BPC-157 but still preliminary. A Phase 2 randomized trial of thymosin beta-4 eye drops in severe dry eye disease showed a 35% reduction in ocular discomfort and 59% reduction in corneal staining at day 56 versus placebo [8]. A small pilot in acute myocardial infarction patients showed improved exercise capacity at six months [9]. Phase 1 safety trials of synthetic TB-4 at doses up to 1,260 mg over 14 days reported no serious adverse events [10]. None of these studies, however, evaluated the musculoskeletal indications most patients are seeking. TB-500 is not Health Canada-approved, is on the WADA Prohibited List for sport, and falls into the same off-label compounded category as the GH peptides above. It was included in the April 2025 Health Canada enforcement action [2].

PT-141 (Bremelanotide)

PT-141 is the regulatory exception in this list. Marketed as Vyleesi, it received FDA approval in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, based on the Phase 3 RECONNECT trials in 1,247 women [11]. It works centrally — activating melanocortin-4 receptors in the brain — rather than on vascular tissue like sildenafil. It's used off-label in men for erectile dysfunction, particularly cases unresponsive to PDE5 inhibitors.

The Canadian status is the key fact for BC residents: Vyleesi is not approved by Health Canada [12]. This means even though there's a fully approved pharmaceutical version of bremelanotide in the US, BC patients seeking it are looking at either compounded preparations on a physician's prescription, or personal-use importation pathways, both of which carry friction. Side effects warrant attention: nausea (in roughly 40% of trial participants), flushing, and notably, hyperpigmentation if used more than eight times per month, which may be permanent [11].

The Legal and Regulatory Reality in Canada

Here's what BC residents need to understand, even if it's uncomfortable: most peptides being marketed in optimization circles are not approved drugs in Canada. They are not in Health Canada's Drug Product Database. They have no Drug Identification Number (DIN). When they're sold by online "research peptide" suppliers, the legal framing — "for research purposes only, not for human use" — is exactly what it sounds like: a disclaimer that allows the product to exist outside the prescription drug framework.

Health Canada's position on unauthorized peptides has hardened. The April 2025 enforcement action against Prime Research (Sherbrooke, QC) — seizing unauthorized injectable peptide drugs and issuing a public advisory warning the public not to use them — was not symbolic [2]. McMaster University researcher Stuart Phillips, in a recent public commentary, was direct about the gap: peptides like BPC-157 lack the human safety and efficacy data needed for regulatory approval, despite their marketing [13].

What "physician-prescribed" actually means in BC is narrower than the marketing suggests. For peptides like sermorelin, ipamorelin, CJC-1295, and TB-500, prescribing in BC means a CPSBC-licensed physician writes a prescription that is filled by a Health Canada-licensed compounding pharmacy. The pharmacy compounds the peptide from active pharmaceutical ingredient under its compounding licence and dispenses it for that specific patient. Several Vancouver-area compounding pharmacies do this work. This is legally distinct from buying "research peptides" online — but it operates in a regulatory grey zone, and not every BC physician is willing to prescribe in this space. Some Canadian wellness clinics explicitly decline to prescribe peptides, citing regulatory uncertainty and the lack of approved indications.

Why grey-market peptides carry real risks: independent testing of online research peptides has found contamination with bacterial endotoxins, incorrect peptide content, dosing inaccuracies, and in some cases the wrong compound entirely. There is no sterility guarantee for an injectable substance produced outside a regulated pharmaceutical facility. Self-injecting an unsterile compound creates infection risk that no anecdotal recovery benefit justifies.

A legitimate peptide prescription in BC involves: a licensed physician (look up CPSBC registration), baseline bloodwork, written contraindication review, a prescription sent to a Health Canada-licensed compounding pharmacy, and structured follow-up. If any of those steps is absent, you're not in a legitimate prescribing pathway — regardless of what the clinic's marketing says.

What to Expect at a Peptide Therapy Clinic in BC

Legitimate physician-supervised peptide programs in BC look broadly similar across reputable providers. The ones described below reflect what genuine clinics — including those listed in our BC longevity and optimization clinics directory — actually do.

Initial consultation (60–90 minutes). A licensed physician or NP takes a full medical history, reviews current medications and supplements, and screens for absolute contraindications. Personal or family history of cancer is a hard stop for GH-stimulating peptides — increasing IGF-1 in someone with a malignancy is a meaningful concern. Active cardiovascular disease, uncontrolled hypertension, and certain endocrine conditions also warrant caution. Goals are discussed honestly: a clinic that promises "30% better recovery" or "10 years off your biological age" is selling marketing, not medicine.

Baseline labs. Expect a comprehensive panel: IGF-1, fasting glucose and HbA1c, full lipid panel, complete metabolic panel, sex hormones (testosterone, estradiol, SHBG), TSH and free T4, and often a CBC. If GH-stimulating peptides are on the table, IGF-1 is the central tracking marker. Some clinics add inflammatory markers (hs-CRP) and vitamin D. See our overview of private lab testing in BC for cost ranges. Initial bloodwork typically runs $200–$450 depending on the panel.

Prescription and dispensing. If you're a candidate, the physician writes a prescription routed to a partnered compounding pharmacy. The pharmacy compounds the peptide, ships it (usually next-day within BC), and the clinic provides injection training. Most peptides on this list are subcutaneous, self-administered with insulin-gauge needles. Dosing is conservative on initiation — building up while monitoring response and side effects.

Monitoring. A responsible protocol re-checks labs at 8–12 weeks. For GH peptides, IGF-1 is tracked to confirm physiological response without overshoot (sustained IGF-1 above the age-adjusted reference range is what you're trying to avoid). Side effect screening, sleep quality, and subjective response are reviewed. Many physicians cycle peptides — typically 3 months on, 4–6 weeks off — to maintain receptor sensitivity, though evidence for cycling protocols is largely empirical.

Cost. Cash-pay only — no extended health plan covers compounded peptide therapy. Realistic monthly ranges: sermorelin $200–$400, CJC-1295/ipamorelin stack $300–$600, BPC-157 (where prescribed) $250–$450, PT-141 prescribed via compounding $200–$400 per month depending on use frequency. Add $150–$300 per follow-up consultation, plus periodic labs. Realistic first-year total for someone on a sustained GH-peptide protocol with quarterly monitoring: $5,000–$8,500.

Who Is a Good Candidate for Peptide Therapy?

The honest answer is that most peptide claims outrun the evidence, and the strongest case for peptide therapy is narrower than its marketing.

Where evidence is strongest (or, less weak): patients with documented adult growth hormone deficiency confirmed on stimulation testing — though these patients are usually candidates for actual growth hormone replacement, not GH-stimulating peptides. Patients with persistent post-injury soft-tissue healing concerns who have exhausted conventional rehabilitation. Patients with HSDD or sexual dysfunction unresponsive to first-line treatment, where bremelanotide has the best regulatory and trial pedigree of any peptide on this list. For these populations, structured physician oversight is essential — not optional.

Who should not pursue peptide therapy. Anyone with a personal or family history of cancer (particularly hormone-sensitive malignancies). Anyone with active cardiovascular disease, uncontrolled diabetes, or significant kidney or liver dysfunction. Anyone pregnant or trying to conceive. Anyone under 25 still in active growth and development. Competitive athletes subject to anti-doping testing — most of these compounds are on the WADA Prohibited List. Anyone whose primary motivation is treating a problem that responds better to evidence-backed first-line interventions: sleep optimization, resistance training, and protein-sufficient nutrition outperform peptides for most "general optimization" goals.

Questions to ask your physician before starting any peptide protocol:

• What is your specific clinical rationale for prescribing this peptide for my situation?
• What does the human trial data actually show for the indication I'm seeking?
• Which compounding pharmacy will fill the prescription, and is it Health Canada-licensed?
• What labs will we track, and at what intervals?
• What's your protocol if I develop side effects or my IGF-1 climbs out of range?
• What does it look like if we discontinue?

A physician who answers those questions specifically — rather than with promotional language about "biological optimization" — is the kind worth working with. For broader help finding qualified providers, see our overview of private specialist access in BC.

FAQ

1. Are peptides legal in Canada?

It depends on the peptide. Some peptides (insulin, semaglutide, tirzepatide) are fully approved Health Canada drugs available by prescription. Others (sermorelin, CJC-1295, ipamorelin, TB-500, BPC-157) are not approved as finished pharmaceutical products in Canada, but can in some cases be compounded by a licensed pharmacy on a physician's prescription — a practice that occupies a genuine regulatory grey area. Selling unauthorized injectable peptides directly to consumers is illegal, and Health Canada has actively enforced against it, including a public advisory and seizure in April 2025 [2].

2. Can I get BPC-157 prescribed by a doctor in BC?

In some cases, yes — but with caveats. BPC-157 is not Health Canada approved, has only one published clinical study in humans for orthopaedic indications [4], and was included in Health Canada's April 2025 enforcement action against unauthorized injectable peptides [2]. Some BC physicians working through licensed compounding pharmacies will prescribe it; many will not, citing the absence of approval and limited human safety data. The FDA placed it in Category 2 in 2023, blocking US compounding [5]. If a BC physician offers to prescribe BPC-157 without bloodwork, contraindication screening, or follow-up, that's a red flag regardless of legality.

3. How much does physician-prescribed peptide therapy cost in BC?

Cash-pay only — extended health plans don't cover compounded peptides. Monthly medication cost ranges from $200 to $600 depending on the peptide and dose. Initial consultation typically runs $250–$500, follow-ups $150–$300, baseline labs $200–$450. A realistic first-year total for someone on a structured protocol with quarterly monitoring is $5,000–$8,500. There is no public-system pathway — BC PharmaCare does not cover any of the peptides discussed in this guide.

4. What is the difference between grey-market and pharmaceutical-grade peptides?

The chemical name may be identical; everything else is not. Pharmaceutical-grade peptides dispensed by a Health Canada-licensed compounding pharmacy are produced under regulated conditions with verified active pharmaceutical ingredient, sterility testing, dose accuracy, and a documented chain of custody. Grey-market "research peptides" sold online are produced without the same regulatory oversight; independent testing has found contamination, incorrect peptide content, and dosing inaccuracies. For anything you're injecting, this difference is not academic — it determines infection risk, dosing reliability, and whether the compound in the vial is what the label says.

5. Do peptides require a prescription in British Columbia?

For any peptide intended for human therapeutic use, yes — a prescription from a CPSBC-licensed physician filled by a licensed pharmacy is the only legitimate pathway. The "research peptide" market that operates without prescriptions does so by labelling products as "not for human use," which is a regulatory loophole, not a green light. Self-prescribing or self-administering injectable peptides obtained outside the prescription framework places you outside any meaningful safety net — no medical oversight, no quality assurance, and no recourse if something goes wrong.

---

References

[1] Drucker DJ. Advances in oral peptide therapeutics. Nature Reviews Drug Discovery, 2020.

[2] Health Canada. Public Advisory: Unauthorized injectable peptide drugs sold by Prime Research may pose serious health risks, April 14, 2025.

[3] Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019;377(2):153–159.

[4] DeFoor MT, Dekker TJ. Injectable therapeutic peptides — an adjunct to regenerative medicine and sports performance? A 2025 systematic review. American Journal of Sports Medicine / Arthroscopy, 2025;41(2):150–152.

[5] U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing materials — BPC-157 Category 2 designation, 2023.

[6] U.S. Food and Drug Administration. Geref (sermorelin acetate) NDA 020443 — discontinued product record.

[7] U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Briefing Document — Ipamorelin and CJC-1295, 2024.

[8] Sosne G, Dunn SP, Kim C. Thymosin Beta-4 Significantly Improves Signs and Symptoms of Severe Dry Eye in a Phase 2 Randomized Trial. Cornea, 2015.

[9] Zhu J et al. Thymosin beta-4 in cardiac repair: a pilot clinical study in acute myocardial infarction. 2016.

[10] Crockford D et al. Phase I clinical trial of recombinant and synthetic thymosin beta-4 in healthy volunteers. Annals of the New York Academy of Sciences, 2010.

[11] Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstetrics and Gynecology, 2019;134(5):899–908.

[12] Health Canada. Drug Product Database — bremelanotide search (no Canadian approval as of April 2026).

[13] Phillips S. Q&A on "research only" peptides. McMaster University News, 2026.

[14] World Anti-Doping Agency. Prohibited List — S0: Non-Approved Substances, current edition.

[15] Perkovic M et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. International Journal of Molecular Sciences, 2025; PMC11859134.

---

This article is intended for residents of British Columbia seeking general information about peptide therapy. Regulatory status, prescribing practices, and the evidence base for individual peptides change frequently; verify current information with Health Canada, your physician, and a licensed compounding pharmacy before making any decisions. BCMedicalAccess.ca is a healthcare navigation resource and does not provide medical advice or prescribe medications.